Mild to moderate hidradenitis suppurativa.
Conditions
Interventions
Bimekizumab with Unilateral Non?ablative Fractional Laser Cohort:Bimekizumab + NAFL (1565 nm)
Sponsors
The second affiliated hospital of Zhejiang University school of medicine
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Patients voluntarily participate in the study and sign the informed consent form; 2. Male or female participants aged >= 18 years and = 1 anatomical region and a total abscess and inflammatory nodule (AN) count >= 3; 5. Participants must have intolerance, contraindication, or inadequate response to oral antibiotic treatment for HS for at least 3 months, or have relapsed after stopping such treatment; 6. Have a basic understanding of the study purpose, the intervention, and possible side effects, and voluntarily sign the informed consent form in accordance with the spirit of the Declaration of Helsinki; 7. Agree to receive regular treatment, attend follow-up visits, and undergo the required examinations and tests as specified in the clinical study protocol; 8. Participants are planned to receive combination therapy with bimekizumab and non-ablative fractional laser (1565 nm), and have not previously received either bimekizumab or non-ablative fractional laser treatment.
Exclusion criteria
Exclusion criteria: 1. Known allergy to the study drug or its excipients; 2. Prior use of biologics or small molecule targeted agents; 3. Presence of tunnels on ultrasound at baseline; diagnosed with inflammatory diseases other than HS; history of chronic or recurrent infections; history of malignancy; 4. History of drug abuse, suicide attempt, or psychiatric disorders; 5. Participated in another clinical trial within the past 3 months; 6. Pregnant or breastfeeding women, or those planning to become pregnant during the study period; 7. Any other condition that, in the opinion of the investigator, would make the participant unsuitable for inclusion; 8. Systemic use of corticosteroids within the past 4 weeks, or topical use within the past 2 weeks;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of Participants Achieving HiSCR (Hidradenitis Suppurativa Clinical Response) and no increase from baseline in abscess or draining tunnel (fistula/sinus tract) count.; | — |
Secondary
| Measure | Time frame |
|---|---|
| Duration of illness; | — |
Countries
China
Contacts
Public ContactJiaqi Chen
The second affiliated hospital of Zhejiang University school of medicine
Outcome results
None listed